Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation

Blood

Volumn 103, Issue 4, 2004, Pages 1244-1252

  Katano, Harutaka ^b   Ali, Mir A ^b   Patera, Andriani C ^b   Catalfamo, Marta ^b   Jaffe, Elaine S ^b   Kimura, Hiroshi ^b   Dale, Janet K ^b   Straus, Stephen E ^b   Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; FAS ANTIGEN; PERFORIN; PROTEIN PRECURSOR; VIRUS ANTIBODY; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CELL STIMULATION; CHILD; CHRONIC ACTIVE EPSTEIN BARR VIRUS INFECTION; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA SEQUENCE; FAMILIAL DISEASE; GENE MUTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPH NODE; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RARE DISEASE; T LYMPHOCYTE; VIRUS INFECTION;

EID: 0842264040     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2171     Document Type: Article

References (56)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481-492.
2. Schooley RT, Carey RW, Miller G, et al. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis: clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med. 1986;104:636-643.
3. Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev Oncol Hematol. 2002;44:273-282.
4. Straus SE. Acute progressive Epstein-Barr virus infections. Annu Rev Med. 1992;43:437-449.
5. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280-286.
6. Alfieri C, Ghibu F, Joncas JH. Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. Can Med Assoc J. 1984;131:1249-1252.
7. Schwarzmann F, von Baehr R, Jager M, et al. A case of severe chronic active infection with Epstein-Barr virus: immunologic deficiencies associated with a lytic virus strain. Clin Infect Dis. 1999;29:626-631.
8. Alfieri C, Joncas JH. Biomolecular analysis of a defective nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. J Virol. 1987;61:3306-3309.
9. Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96:443-451.
10. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129-135.
11. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765-13770.
12. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462-469.
13. Fujieda M, Wakiguchi H, Hisakawa H, Kubota H, Kurashige T. Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents. Acta Paediatr Jpn. 1993;35:394-399.
14. Joncas J, Monczak Y, Ghibu F, et al. Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J Med Virol. 1989;28:110-117.
15. Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33:388-391.
16. Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr. 1999;135:640-643.
17. Helminen M, Lahdenpohja N, Hurme M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis. 1999;180:496-499.
18. Czar MJ, Kersh EN, Mijares LA, et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1 A/DSHP/SAP. Proc Natl Acad Sci U S A. 2001;98:7449-7454.
19. Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood. 1996;87:1446-1457.
20. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-1959.
21. Straus SE. The chronic mononucleosis syndrome. J Infect Dis. 1988;157:405-412.
22. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18:29-33.
23. Feldmann J, Le Deist F, Ouachee-Chardin M, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2002;117:965-972.
24. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78:2918-2922.
25. Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis. 2001;183:1-7.
26. Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol. 2001;82:2385-2392.
27. Ueda I, Morimoto A, Inaba T, et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br J Haematol. 2003;121:503-510.
28. Hameed A, Olsen KJ, Cheng L, Fox WM 3rd, Hruban RH, Podack ER. Immunohistochemical identification of cytotoxic lymphocytes using human perforin monoclonal antibody. Am J Pathol. 1992;140:1025-1030.
29. Uellner R, Zvelebil MJ, Hopkins J, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. Embo J. 1997;16:7287-7296.
30. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol. 1995;154:6122-6131.
31. Kawasaki A, Shinkai Y, Kuwana Y, et al. Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cells. Int Immunol. 1990;2:677-684.
32. Menasche G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25:173-176.
33. Haddad EK, Wu X, Hammer JA 3rd, Henkart PA. Defective granule exocytosis in Rab27a-deficient lymphocytes from Ashen mice. J Cell Biol. 2001;152:835-842.
34. Sanal O, Ersoy F, Tezcan I, et al. Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity. J Clin Immunol. 2002;22:237-243.
35. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31-37.
36. van den Broek MF, Hengartner H. The role of perforin in infections and tumour surveillance. Exp Physiol. 2000;85:681-685.
37. Walsh CM, Matloubian M, Liu CC, et al. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A. 1994;91:10854-10858.
38. Ghiasi H, Cai S, Perng G, Nesburn AB, Wechsler SL. Perforin pathway is essential for protection of mice against lethal ocular HSV-1 challenge but not corneal scarring. Virus Res. 1999;65:97-101.
39. Mullbacher A, Hla RT, Museteanu C, Simon MM. Perforin is essential for control of ectromelia virus but not related poxviruses in mice. J Virol. 1999;73:1665-1667.
40. Yoshimi A, Tsuge J, Namizaki H, et al. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation. Br J Haematol. 2002;116:710-715.
41. Khanolkar A, Yagita H, Cannon MJ. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4- T cells. Virology. 2001;287:79-88.
42. Sun Q, Burton RL, Pollok KE, Emanuel DJ, Lucas KG. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol. 1999;195:81-88.
43. Zanussi S, Vaccher E, Caffau C, et al. Interferon-gamma secretion and perforin expression are impaired in CD8(+) T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother. 2003;52:28-32.
44. Zhang D, Shankar P, Xu Z, et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood. 2003;101:226-235.
45. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3:1061-1068.
46. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192:755-760.
47. Arico M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis: report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 1996;10:197-203.
48. Henter JI, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis: primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12:417-433.
49. Goransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet. 2001;68:590-597.
50. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44:259-272.
51. Ma X, Okamura A, Yosioka M, Ishiguro N, Kikuta H, Kobayashi K. No mutations of SAP/SH2D1A/DSHP and perforin genes in patients with Epstein-Barr virus-associated hemophagocytic syndrome in Japan. J Med Virol. 2001;65:358-361.
52. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61-66.
53. Arnaout RA. Perforin deficiency: fighting unarmed? Immunol Today. 2000;21:592.
54. Moretta L, Moretta A, Hengartner H, Zinkernagel RM. On the pathogenesis of perforin defects and related immunodeficiencies. Immunol Today. 2000;21:593-594.
55. Ishii E, Kimura N, Kato K, et al. Clonal change of infiltrating T-cells in children with familial hemophagocytic lymphohistiocytosis: possible association with Epstein-Barr virus infection. Cancer. 1999;85:1636-1643.
56. Tsuge I, Morishima T, Kimura H, Kuzushima K, Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol. 2001;64:141-148.